Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Triamcinolone Action Pathway
Homo sapiens
Drug Action Pathway
Triamcinolone is a glucocorticoid used to treat a wide variety of inflammatory conditions. As this drug is a glucocorticoid, its mechanism of action is that of the glucocorticoid response element (GRE) influencing COX-2/prostaglandin G/H synthase 2 suppression and lipocortin/annexin induction. By binding to the glucocorticoid receptor, it influences transcription factors AP-1 and NF-kB to block the transcription of COX-2/prostaglandin G/H synthase 2 which reduces the amount of prostanoids being produced from arachidonic acid. Prostanoids such as PGI2 and thromboxane A2 influence the effects of inflammation through vasoconstriction/dilation, pain sensitivity, and platelet aggregation. Triamcinolone also affects the promoter of annexin-1, an important inflammatory protein as it affects leukocytes and blocks phospholipase A2 which reduces the amount of arachidonic acid being cleaved from the phospholipid bilayer. Reducing the amount of arachidonic acid formed further decreases the concentrations of prostanoids mentioned calming inflammation. This drug is available as tablets, eye drops, creams, intramuscular and intravenous injections, and as a nasal spray.
References
Triamcinolone Pathway References
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Pubmed: 29126136
Hochhaus G, Portner M, Barth J, Mollmann H, Rohdewald P: Oral bioavailability of triamcinolone tablets and a triamcinolone diacetate suspension. Pharm Res. 1990 May;7(5):558-60. doi: 10.1023/a:1015889305157.
Pubmed: 1973290
Schweitzer DH, Le-Brun PP, Krishnaswami S, Derendorf H: Clinical and pharmacological aspects of accidental triamcinolone acetonide overdosage: a case study. Neth J Med. 2000 Jan;56(1):12-6. doi: 10.1016/s0300-2977(99)00085-6.
Pubmed: 10667036
Derendorf H, Hochhaus G, Rohatagi S, Mollmann H, Barth J, Sourgens H, Erdmann M: Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol. 1995 Mar;35(3):302-5. doi: 10.1002/j.1552-4604.1995.tb04064.x.
Pubmed: 7608322
Nehme A, Lobenhofer EK, Stamer WD, Edelman JL: Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells. BMC Med Genomics. 2009 Sep 10;2:58. doi: 10.1186/1755-8794-2-58.
Pubmed: 19744340
Issar M, Sahasranaman S, Buchwald P, Hochhaus G: Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur Respir J. 2006 Mar;27(3):511-6. doi: 10.1183/09031936.06.00060005.
Pubmed: 16507850
Shahin V, Ludwig Y, Schafer C, Nikova D, Oberleithner H: Glucocorticoids remodel nuclear envelope structure and permeability. J Cell Sci. 2005 Jul 1;118(Pt 13):2881-9. doi: 10.1242/jcs.02429.
Pubmed: 15976447
Kim S. W, Ko J, Kim J. H, Choi E. C, Na D. S. Differential effects of annexins I, II, III, and V on cytosolic phospholipase A2 activity: specific interaction model. FEBS Letters 489: 243-248, 2001.
Necela B. M, Cidlowski J. A. Mechanisms of Glucocorticoid Receptor Action in Noninflammatory and Inflammatory Cells. American Thoracic Society 1:239-246, 2004.
Perretti M, Dalli J. Exploiting the Annexin A1 pathway for the development of novel anti-inflammatory therapeutics. British Journal of Pharmacology 158: 936-946, 2009.
Oeckinghaus A, Ghosh S. The NF-kB Family of Transcription Factors and Its Regulation. Cold Spring Harb Perspect Biol 1(4): a000034, 2009.
Caldenhoven E, Liden J, Wissink S, Wan de Stolpe A, Raaijmakers J, Koenderman L, Okret S, Gustafsson J, Van der Saag P, T. Negative Cross-Talk between ReAl and the Glucocorticoid Receptor: A Possible Mechanism for the Anti-inflammatory Action of Glucocorticoids. Molecular Endocrinology 9(4): 401-412, 1995.
Kang Y, Mbonye U. R, DeLong C. J, Wada M, Smith W. L. Regulation of Intracellular Cyclooxygenase Levels by Gene Transcription and Protein Degradation. Prog Lipid Res 46(2): 108-125, 2007.
Kirschke E, Goswami D, Southworth D, Griffin P. R, Agard D. Glucocorticoid Receptor Function Regulated by Coordinated Action of the Hsp90 and Hsp70 Chaperone Cycles. Cell 157(7): 1685-1697, 2014.
Parente L, Solito E. Annexin 1: more than an anti-phospholipase protein. Inflammation Research 53: 125-132, 2004.
Liu T, Zhang L, Joo D, Sun S. NF-κB signaling in inflammation. Signal Transduction and Targeted Therapy 2: 17023, 2017.
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings